Drugs / TAK-915
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02584569 | Nov 2015 → Apr 2016 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02461160 | May 2015 → Aug 2016 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK915 | “Regimen A: TAK915 50 mg oral suspension formulation in fasted state; Regimen B: TAK-915 50 tablet formulation in fasted state; Regimen C: TAK-915 50 tablet formulation in fasted state).” NCT02461160 ↗ |
| Modality | Small molecule | — CHEMBL4060569 ↗ |
| Route | Oral | “TAK-915 30 mg suspension, orally, once on Day 1.” NCT02461160 ↗ |